课题基金 / 基金详情

ROSWELL PARK CANCER INSTITUTE CENTER SUPPORT GRANT

ROSWELL PARK CANCER INSTITUTE CENTER SUPPORT GRANT
罗斯威尔公园癌症研究所中心支持补助金
批准号:
2414072
负责人:
YOUCEF M RUSTUM
金额:
$196.57万
依托单位国家:
美国
项目类别:
财政年份:
1983
资助国家:
美国
项目状态:
已结题
起止时间:
1983-12-01 至 2000-04-30

项目摘要

项目成果

YOUCEF M RUSTUM的其他基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
This is a competitive renewal application for the Cancer Center Support Grant of Roswell Park Cancer Institute (RPCI). an NCI-designated Comprehensive Cancer Center, for the grant period 1985 - 2000. Under the leadership of Institute President and CEO, Thomas B. Tomasi, M.D., Ph.D, this grant is entering its 20th year of uninterrupted funding. Over the past two decades, the CCSG has provided indispensable support to the research programs of RPCI. The present CCSG application reflects the significant evolution and progress of RPCIs research programs with the inclusion of 6 mature programs, 2 developing programs and 12 shared resources, seven of which are new or significantly expanded resources carried over from the merger of the Institute Core Grant with the Grace Cancer Drug Center Core Grant. Since the last CCSG renewal, there have been numerous changes in the RPCI research programs including recruitment of new senior faculty, scientific and clinical departments have been reorganized, major capital investments and the commitment of New York State to design and build a new research laboratory, vivarium, nursing tower, ambulatory clinic and diagnostic and treatment facility, all in addition to major renovations to existing research facilities. The CCSG plays a central role in the planning and evaluation, support and administration of Roswell's basic and clinical research programs. With the renewal of this CCSG, combined with the commitment of New York State to support the cancer mission of Roswell Park and its highly dedicated research faculty, Roswell Park will be poised to enter the next century as one of the nations leading cancer centers.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
IMPROVING ANIMAL RESOURCES FOR CANCER RESEARCH AT RPCI
Irinotecan in Combination with Celecoxib: A phase I Stu*
ROSWELL PARK DNA REPLICATION PROG FACIL: ANTITUMOR DRUG
ROSWELL PARK DNA REPLICATION PROG FACIL: GENET SMOKING